PortalPublikationenHumoral immune response to tick-borne encephalitis vaccinati...

Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients

Standard

Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients. / Harrison, Nicole; Grabmeier-Pfistershammer, Katharina; Graf, Alexandra; Schwarzinger, Ilse; Aberle, Judith H.; Stiasny, Karin; Greinix, Hildegard; Rabitsch, Werner; Kalhs, Peter; Ramharter, Michael; Burgmann, Heinz; Forstner, Christina.

in: NPJ VACCINES, Jahrgang 5, Nr. 1, 67, 01.12.2020, S. 67.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Harrison, N, Grabmeier-Pfistershammer, K, Graf, A, Schwarzinger, I, Aberle, JH, Stiasny, K, Greinix, H, Rabitsch, W, Kalhs, P, Ramharter, M, Burgmann, H & Forstner, C 2020, 'Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients', NPJ VACCINES, Jg. 5, Nr. 1, 67, S. 67. https://doi.org/10.1038/s41541-020-00215-1

APA

Harrison, N., Grabmeier-Pfistershammer, K., Graf, A., Schwarzinger, I., Aberle, J. H., Stiasny, K., Greinix, H., Rabitsch, W., Kalhs, P., Ramharter, M., Burgmann, H., & Forstner, C. (2020). Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients. NPJ VACCINES, 5(1), 67. [67]. https://doi.org/10.1038/s41541-020-00215-1

Vancouver

Harrison N, Grabmeier-Pfistershammer K, Graf A, Schwarzinger I, Aberle JH, Stiasny K et al. Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients. NPJ VACCINES. 2020 Dez 1;5(1):67. 67. https://doi.org/10.1038/s41541-020-00215-1

Bibtex

@article{e87ea7a6f167485b8b23e93bd10f6399,
title = "Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients",
abstract = "The aim of this prospective study was to characterize the humoral immune response to TBE vaccination after hematopoietic stem cell transplantation (HSCT). Nineteen adult patients 11–13 months after HSCT and 15 age-matched immunocompetent adults received up to three TBE vaccinations. Antibodies against TBE virus were measured by neutralization test (NT). As primary endpoint, the antibody response (NT titer of ≥10 and at least a twofold increase from baseline 4 weeks after second vaccination) was compared between patients and controls using Fisher exact test. Prior vaccination, 15 (79%) HSCT patients still had detectable neutralizing antibodies. At primary endpoint, the antibody response was significantly lower in patients than in controls (35% versus 93%; p < 0.001). The CD4+ cell count was a predictor for an antibody response in patients (p = 0.019). Interestingly, the majority of HSCT patients still had detectable antibodies prior vaccination. Following vaccination, antibody response in HSCT patients was associated with the CD4+ cell count.",
author = "Nicole Harrison and Katharina Grabmeier-Pfistershammer and Alexandra Graf and Ilse Schwarzinger and Aberle, {Judith H.} and Karin Stiasny and Hildegard Greinix and Werner Rabitsch and Peter Kalhs and Michael Ramharter and Heinz Burgmann and Christina Forstner",
note = "{\textcopyright} The Author(s) 2020.",
year = "2020",
month = dec,
day = "1",
doi = "10.1038/s41541-020-00215-1",
language = "English",
volume = "5",
pages = "67",
journal = "NPJ VACCINES",
issn = "2059-0105",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients

AU - Harrison, Nicole

AU - Grabmeier-Pfistershammer, Katharina

AU - Graf, Alexandra

AU - Schwarzinger, Ilse

AU - Aberle, Judith H.

AU - Stiasny, Karin

AU - Greinix, Hildegard

AU - Rabitsch, Werner

AU - Kalhs, Peter

AU - Ramharter, Michael

AU - Burgmann, Heinz

AU - Forstner, Christina

N1 - © The Author(s) 2020.

PY - 2020/12/1

Y1 - 2020/12/1

N2 - The aim of this prospective study was to characterize the humoral immune response to TBE vaccination after hematopoietic stem cell transplantation (HSCT). Nineteen adult patients 11–13 months after HSCT and 15 age-matched immunocompetent adults received up to three TBE vaccinations. Antibodies against TBE virus were measured by neutralization test (NT). As primary endpoint, the antibody response (NT titer of ≥10 and at least a twofold increase from baseline 4 weeks after second vaccination) was compared between patients and controls using Fisher exact test. Prior vaccination, 15 (79%) HSCT patients still had detectable neutralizing antibodies. At primary endpoint, the antibody response was significantly lower in patients than in controls (35% versus 93%; p < 0.001). The CD4+ cell count was a predictor for an antibody response in patients (p = 0.019). Interestingly, the majority of HSCT patients still had detectable antibodies prior vaccination. Following vaccination, antibody response in HSCT patients was associated with the CD4+ cell count.

AB - The aim of this prospective study was to characterize the humoral immune response to TBE vaccination after hematopoietic stem cell transplantation (HSCT). Nineteen adult patients 11–13 months after HSCT and 15 age-matched immunocompetent adults received up to three TBE vaccinations. Antibodies against TBE virus were measured by neutralization test (NT). As primary endpoint, the antibody response (NT titer of ≥10 and at least a twofold increase from baseline 4 weeks after second vaccination) was compared between patients and controls using Fisher exact test. Prior vaccination, 15 (79%) HSCT patients still had detectable neutralizing antibodies. At primary endpoint, the antibody response was significantly lower in patients than in controls (35% versus 93%; p < 0.001). The CD4+ cell count was a predictor for an antibody response in patients (p = 0.019). Interestingly, the majority of HSCT patients still had detectable antibodies prior vaccination. Following vaccination, antibody response in HSCT patients was associated with the CD4+ cell count.

UR - http://www.scopus.com/inward/record.url?scp=85088539303&partnerID=8YFLogxK

U2 - 10.1038/s41541-020-00215-1

DO - 10.1038/s41541-020-00215-1

M3 - SCORING: Journal article

C2 - 32728481

AN - SCOPUS:85088539303

VL - 5

SP - 67

JO - NPJ VACCINES

JF - NPJ VACCINES

SN - 2059-0105

IS - 1

M1 - 67

ER -